Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

NCT02353715 · clinicaltrials.gov ↗

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Abiraterone acetate
DRUG: Sipuleucel-T

Sponsor

Duke University